Effect of periodontal therapy on general health – is there a missing component in the design of these clinical trials?


In the past decade there has been a dramatic increase in literature dealing with the potential impact of periodontal infections on overall general health (Kinane & Bouchar 2008). Strong biologically plausible arguments can be made supporting this connection. In addition, results of many (but not all) epidemiological studies indicate that periodontal infections increase the risk of adverse health outcomes such as cardiovascular disease (Mustapha et al. 2007, Persson & Persson 2008), preterm birth (Xiong et al. 2006, Wimmer & Pihlstrom 2008) and pre-eclampsia (Conde-Agudelo et al. 2008). These association studies are important, but if periodontal infections truly have measurable effects on general health outcomes, treatment of these infections should reduce the incidence and severity of these outcomes.

One of the scientific sessions at the recent International Conference on Periodontal Research held in Ljubljana, Slovenia, dealt with randomized clinical trials (RCT) designed to evaluate the effects of periodontal therapy on general health outcomes. A lively discussion occurred after I pointed out that there appears to be a critically important component missing in the design of these clinical trials. Almost without exception, published intervention trials in this area have no defined periodontal treatment goals or clinically acceptable endpoints linked to the resolution of periodontal infections. The “Material and Methods” sections of most clinical trials adequately describe the periodontal interventions, but fail to include endpoint criteria that can be used to assess the resolution of periodontal infections.

For example, in a large well-performed RCT on a US population [i.e., the Obstetric & Periodontal Therapy (OPT) study], it was found that periodontal treatment did not significantly alter the rates of pre-term birth, low birth weight or foetal development (Michalowicz et al. 2006). The non-surgical periodontal therapy delivered in the OPT study was appropriate in that it included oral hygiene instructions, scaling and root planing (SRP), monthly evaluation and additional scaling “as needed.” Although this treatment regimen was reasonable, the study design did not include pre-determined outcome criteria for successful periodontal therapy. This design problem became apparent after completion of the study when the data showed that the treated subjects still had bleeding on probing (BOP) at an average of 46.9% of sites after treatment. This was a statistically significant decrease in the percentage of sites with BOP compared with baseline values of 69.6%, but most clinicians would regard such a high post-treatment percentage of BOP sites as an unacceptable periodontal outcome. In a non-pregnant population with 68% of the sites exhibiting BOP before SRP, it has been reported that average post-treatment BOP values can be reduced to approximately 10% (Apatzidou & Kinane 2004). It can be argued that it is unreasonable to expect in pregnant individuals that the percentage of sites with BOP can be decreased to levels in the 10–15% range as there are profound perturbations in the maternal immune system during pregnancy (Poole & Claman 2004). However, this argument is difficult to support as non-surgical periodontal therapy in pregnant individuals has been shown to reduce the percentage of sites with BOP to 11–15% (López et al. 2002, 2005, Offenbacher et al. 2006). Interestingly, these studies, which showed a dramatic reduction in BOP, also found that periodontal therapy lowered the risk of adverse pregnancy outcomes.

When RCTs are being designed to evaluate the effect of periodontal therapy on general health outcomes, it is critically important that a clinically acceptable targeted endpoint for successful periodontal therapy be included in the study design. It should not be assumed that simply because periodontal treatment has been performed, it has necessarily been effective in managing the patient’s periodontal infection. Inclusion of a defined therapeutic endpoint could be considered impractical as all patients do not respond in an identical or predictable fashion to conventional periodontal therapy. This is a real problem since in a large population-based RCT it is not feasible to include...
a wide range of treatment modalities (e.g., SRP alone, SRP + multiple antimicrobial agents, SRP + periodontal surgery). Meaningful analysis of the data would be a nightmare as there would be too many intervention variables. However, it is possible to choose a cost-effective and practical form of periodontal therapy that can be expected to work in the majority of the study population. If clinically relevant periodontal outcomes were used, the patients could be placed into responder quartiles for purposes of data analysis. Alternatively, the patients could be dichotomized in responder and non-responder categories. The important point is that the criteria for successful periodontal therapy (i.e., responder and non-responder criteria) be established before conducting the study.

Establishment of clinically relevant criteria for successful periodontal therapy will require a considerable amount of thought and widespread consultation. Since periodontal infections contribute to the inflammatory–infectious burden carried by the patient, the criteria for successful periodontal therapy must include clinical assessments that are linked to this burden. For example, since a composite of probing depth and BOP has been shown to be related to systemic markers of inflammation (Beck & Offenbacher 2002), these two clinical assessments should probably be included as part of any definition of successful periodontal therapy. It is strongly urged that planners of RCT’s seek a consensus from the periodontal community as to what clinical criteria should be used for successful periodontal therapy in future clinical trials.

References


Address:

Gary C. Armitage
Division of Periodontology
University of California
521 Parnassus Avenue C-628, San Francisco
CA 94143-0650
USA
E-mail: Gary.Armitage@ucsf.edu

© 2008 The Authors
Journal compilation © 2008 Blackwell Munksgaard